516 patents
Page 13 of 26
Utility
Bicyclic heterocycles as FGFR4 inhibitors
16 Nov 21
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 12 Mar 20
Utility
Salts of an FGFR inhibitor
16 Nov 21
The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.
Zhongjiang Jia, Jiacheng Zhou, Qun Li
Filed: 3 May 19
Utility
Heterocyclic Compounds As Immunomodulators
11 Nov 21
Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
Filed: 11 Dec 20
Utility
Fused pyrimidine derivatives as A2A / A2B inhibitors
9 Nov 21
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
Filed: 17 May 19
Utility
Tricyclic fused thiophene derivatives as JAK inhibitors
2 Nov 21
The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
Filed: 27 Jun 19
Utility
Heterocyclic derivatives as PI3K inhibitors
2 Nov 21
Stacey Shepard, Yanran Ai, Andrew P. Combs, Artem Shvartsbart
Filed: 12 Nov 19
Utility
Fused pyrazine derivatives as A2A / A2B inhibitors
2 Nov 21
Xiaozhao Wang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu
Filed: 3 Jul 19
Utility
Use of Pyrazolopyrimidine Derivatives for the Treatment of PI3K-DELTA Related Disorders
28 Oct 21
Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
Filed: 30 Jun 21
Utility
Tricyclic Heteroaryl Compounds As Sting Activators
28 Oct 21
The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Yingda Ye, Wenqing Yao
Filed: 4 May 21
Utility
Cyclopropylamines as LSD1 inhibitors
26 Oct 21
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Wenqing Yao
Filed: 1 May 20
Utility
Heterocyclic Compounds As Immunomodulators
14 Oct 21
Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
Filed: 19 Nov 20
Utility
Pyrrolopyrimidine derivatives as TAM inhibitors
5 Oct 21
Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
Filed: 15 Nov 19
Utility
Salts of an LSD1 Inhibitor and Processes for Preparing the Same
30 Sep 21
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 12 Mar 21
Utility
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
30 Sep 21
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 4 Jun 21
Utility
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
28 Sep 21
Yun-Long Li, Andrew P. Combs
Filed: 8 Oct 19
Utility
Heterocyclic compounds as immunomodulators
21 Sep 21
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 23 Apr 20
Utility
Combination Therapy Comprising Axl/mer and PD-1/PD-L1 Inhibitors
9 Sep 21
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Jonathan Rios-Doria, Holly K. Koblish
Filed: 5 Mar 21
Utility
Pyrazolopyrimidine compounds and uses thereof
7 Sep 21
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
Filed: 24 Sep 19
Utility
Tricyclic Compounds As Inhibitors of Kras
2 Sep 21
Xiaozhao Wang, Wenyu Zhu, Jeffrey Yang, Alexander Sokolsky, Chunhong He, Zhenwu Li, Chao Qi, Yong Li, Pei Gan, Peter Carlsen, Gia Hoang, Heeoon Han, Chenyin Marshall Law, Fenglei Zhang, Padmaja Polam, Le Zhao, Liangxing Wu, Wenqing Yao
Filed: 8 Jan 21
Utility
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
31 Aug 21
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 14 Feb 19